SUPN Files 8-K for 'Other Event'; Routine Admin Update
Ticker: SUPN · Form: 8-K · Filed: 2024-02-05T00:00:00.000Z
Sentiment: neutral
Topics: administrative, corporate-governance, 8-K
TL;DR
**SUPN filed a routine 8-K, no big news, just administrative updates.**
AI Summary
Supernus Pharmaceuticals, Inc. filed an 8-K on February 5, 2024, to report an "Other Event." This filing primarily updates administrative details, confirming its status as a Delaware corporation with its principal executive offices at 9715 Key West Ave, Rockville, MD, and its common stock (SUPN) listed on The Nasdaq Stock Market LLC. This matters to investors because it's a routine administrative update, indicating no immediate significant operational or financial changes, which can be reassuring for current or prospective shareholders.
Why It Matters
This filing is a standard administrative update, signaling no major immediate changes to Supernus Pharmaceuticals' operations or financial health. It provides transparency on basic company information for investors.
Risk Assessment
Risk Level: low — This 8-K is a routine administrative filing with no material financial or operational disclosures, posing minimal risk.
Analyst Insight
A smart investor would view this as a non-event, confirming basic company details but providing no new information to alter investment decisions. It's a good reminder to check for more substantive filings for operational or financial updates.
Key Numbers
- 001-35518 — Commission File Number (identifies Supernus Pharmaceuticals, Inc. with the SEC)
- 301-838-2500 — Business Phone Number (contact information for Supernus Pharmaceuticals, Inc.)
- $0.001 — par value per share (par value of Supernus Pharmaceuticals, Inc.'s Common Stock)
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
- Delaware (company) — state of incorporation for Supernus Pharmaceuticals, Inc.
- The Nasdaq Stock Market LLC (company) — exchange where Supernus Pharmaceuticals, Inc.'s common stock is registered
- February 5, 2024 (date) — date of earliest event reported and filing date
- 9715 Key West Ave Rockville MD 20850 (company) — address of principal executive offices for Supernus Pharmaceuticals, Inc.
- SUPN (company) — trading symbol for Supernus Pharmaceuticals, Inc.
Forward-Looking Statements
- Supernus Pharmaceuticals, Inc. will continue to operate without significant immediate changes to its corporate structure or listing status. (Supernus Pharmaceuticals, Inc.) — high confidence, target: 2024-12-31
FAQ
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing was February 5, 2024.
What is the trading symbol for Supernus Pharmaceuticals, Inc.'s common stock?
The trading symbol for Supernus Pharmaceuticals, Inc.'s common stock is SUPN, and it is registered on The Nasdaq Stock Market LLC.
Where are Supernus Pharmaceuticals, Inc.'s principal executive offices located?
Supernus Pharmaceuticals, Inc.'s principal executive offices are located at 9715 Key West Ave, Rockville, MD 20850.
What is the state of incorporation for Supernus Pharmaceuticals, Inc.?
Supernus Pharmaceuticals, Inc. is incorporated in Delaware.
What is the par value per share for Supernus Pharmaceuticals, Inc.'s Common Stock?
The par value per share for Supernus Pharmaceuticals, Inc.'s Common Stock is $0.001.
Filing Stats: 487 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-02-05 09:21:51
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Sto
Filing Documents
- supn-20240205.htm (8-K) — 27KB
- ex99102-05x2024.htm (EX-99.1) — 11KB
- image_0.jpg (GRAPHIC) — 5KB
- 0001356576-24-000003.txt ( ) — 171KB
- supn-20240205.xsd (EX-101.SCH) — 2KB
- supn-20240205_lab.xml (EX-101.LAB) — 24KB
- supn-20240205_pre.xml (EX-101.PRE) — 12KB
- supn-20240205_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On February 5, 2024, Supernus Pharmaceuticals, Inc. ("Supernus") issued a press release announcing that the United States District Court for the District of New Jersey ruled that Torrent Pharmaceuticals Ltd. Torrent Group and its subsidiary, Torrent Pharma Inc., infringed three patents by submitting to the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) seeking permission to market a generic version of Trokendi XR before the expiration of Supernus' patents. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibit The following document is furnished as an Exhibit pursuant to Item 8.01 hereof: Exhibit 99.1 — Press Release Dated February 5, 2024 . 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: February 5, 2024 By: /s/ Timothy C. Dec Timothy C. Dec Senior Vice President and Chief Financial Officer 3